Get our summary of the big beta-blocker late breaking research results out of #ESCCongress! 🫀
Highlights from BETAMI-DANBLOCK and REBOOT-CNIC and other trials available here ➡️ https://bit.ly/4mFtGRd
Highlights from BETAMI-DANBLOCK and REBOOT-CNIC and other trials available here ➡️ https://bit.ly/4mFtGRd
August 30, 2025 at 6:00 PM
Get our summary of the big beta-blocker late breaking research results out of #ESCCongress! 🫀
Highlights from BETAMI-DANBLOCK and REBOOT-CNIC and other trials available here ➡️ https://bit.ly/4mFtGRd
Highlights from BETAMI-DANBLOCK and REBOOT-CNIC and other trials available here ➡️ https://bit.ly/4mFtGRd
BETAMI–DANBLOCK trial: Beta-blockers are recommended for myocardial infarction and reduced left ventricular ejection fraction, but potential benefits for preserved or mildly reduced ejection fraction are unclear. Research findings are summarized in a new Quick Take video. nej.md/41DqahQ
September 10, 2025 at 3:01 PM
BETAMI–DANBLOCK trial: Beta-blockers are recommended for myocardial infarction and reduced left ventricular ejection fraction, but potential benefits for preserved or mildly reduced ejection fraction are unclear. Research findings are summarized in a new Quick Take video. nej.md/41DqahQ
Among patients with myocardial infarction and a left ventricular ejection fraction of at least 40%, beta-blockers led to a lower risk of death or major cardiovascular events than no beta-blocker therapy. Full BETAMI–DANBLOCK trial results and Research Summary: nej.md/4oT6aSg
#MedSky
#MedSky
September 2, 2025 at 4:06 PM
Among patients with myocardial infarction and a left ventricular ejection fraction of at least 40%, beta-blockers led to a lower risk of death or major cardiovascular events than no beta-blocker therapy. Full BETAMI–DANBLOCK trial results and Research Summary: nej.md/4oT6aSg
#MedSky
#MedSky
i've never really understood the appeal of danblock (other than just that people will make yaoi out of anything) but i just had a moment of thinking of them as kind of the mirror of what's going on with artemy and aglaya... thematically interesting in that case at least.
July 16, 2025 at 6:13 PM
i've never really understood the appeal of danblock (other than just that people will make yaoi out of anything) but i just had a moment of thinking of them as kind of the mirror of what's going on with artemy and aglaya... thematically interesting in that case at least.
1/ Newer data is reshaping post-MI β-blocker strategy. REBOOT shows no benefit when EF>40% in patients receiving modern invasive/medical therapy, while pooled data from BETAMI, DANBLOCK, and CAPITAL-RCT suggest benefit in the EF 40–49% range. #medsky #pharmsky #emimcc #cardiosky
a woman says " no need for that " while wearing a jacket
ALT: a woman says " no need for that " while wearing a jacket
media.tenor.com
November 15, 2025 at 6:27 AM
1/ Newer data is reshaping post-MI β-blocker strategy. REBOOT shows no benefit when EF>40% in patients receiving modern invasive/medical therapy, while pooled data from BETAMI, DANBLOCK, and CAPITAL-RCT suggest benefit in the EF 40–49% range. #medsky #pharmsky #emimcc #cardiosky
【備忘】Apr.22
EHJ誌に「β遮断薬はいつ使えば安全？実用的オープン試験データにおける症候性の鬱と不安」と題する論説 [詳細不詳]。
図解抄録🔗 academic.oup.com/eurheartj/ad...
EHJ誌に「β遮断薬はいつ使えば安全？実用的オープン試験データにおける症候性の鬱と不安」と題する論説 [詳細不詳]。
図解抄録🔗 academic.oup.com/eurheartj/ad...
When are beta-blockers safe to use? Symptoms of depression and anxiety in aggregated data of pragmatic open-label trials
This editorial refers to ‘Beta-blockers, depression, and anxiety after myocardial infarction: the BETAMI-DANBLOCK trial’, by J.E. Nyen et al., https://doi.
academic.oup.com
April 22, 2026 at 10:46 PM
【備忘】Apr.22
EHJ誌に「β遮断薬はいつ使えば安全？実用的オープン試験データにおける症候性の鬱と不安」と題する論説 [詳細不詳]。
図解抄録🔗 academic.oup.com/eurheartj/ad...
EHJ誌に「β遮断薬はいつ使えば安全？実用的オープン試験データにおける症候性の鬱と不安」と題する論説 [詳細不詳]。
図解抄録🔗 academic.oup.com/eurheartj/ad...
On this episode of Talking Points, C. Michael Gibson and Dan Atar discuss the BETAMI-DANBLOCK trial and the impact of discontinuing beta-blockers after MI in patients without HF. Listen now: www.tctmd.com/audio/betami...
July 22, 2026 at 7:16 PM
On this episode of Talking Points, C. Michael Gibson and Dan Atar discuss the BETAMI-DANBLOCK trial and the impact of discontinuing beta-blockers after MI in patients without HF. Listen now: www.tctmd.com/audio/betami...
The BETAMI-DANBLOCK Trial
The BETAMI-DANBLOCK Trial
The BETAMI-DANBLOCK Trial
cmacahilig@crf.org
Wed, 07/22/2026 - 09:47
1 minute 12 seconds ago
How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.
www.tctmd.com
July 22, 2026 at 1:54 PM
The BETAMI-DANBLOCK Trial
DREAMS COME TRUE! (Part One): THE DANNY TOBIAS SEPTET (DANNY TOBIAS, DAN BLOCK, SCOTT ROBINSON, STEVE ASH, FELIX LEMERLE, JEN HODGE, ALEX RADERMAN at Winnie's Jazz Bar, March 14, 2025)
jazzlives.wordpress.com/2025/03/26/d...
#jazz #ScottRobinson #DanBlock #DannyTobias jazzsky
jazzlives.wordpress.com/2025/03/26/d...
#jazz #ScottRobinson #DanBlock #DannyTobias jazzsky
DREAMS COME TRUE! (Part One): THE DANNY TOBIAS SEPTET (DANNY TOBIAS, DAN BLOCK, SCOTT ROBINSON, STEVE ASH, FELIX LEMERLE, JEN HODGE, ALEX RADERMAN at Winnie’s Jazz Bar, March 14, 2025)
My title is no overstatement. The people: The place: That’s one view of Winnie’s Jazz Bar, 63 West 38th Street, New York, NY 10018 (646) 846-9063. Cozy, friendly, with very nice food an…
jazzlives.wordpress.com
March 26, 2025 at 1:01 PM
DREAMS COME TRUE! (Part One): THE DANNY TOBIAS SEPTET (DANNY TOBIAS, DAN BLOCK, SCOTT ROBINSON, STEVE ASH, FELIX LEMERLE, JEN HODGE, ALEX RADERMAN at Winnie's Jazz Bar, March 14, 2025)
jazzlives.wordpress.com/2025/03/26/d...
#jazz #ScottRobinson #DanBlock #DannyTobias jazzsky
jazzlives.wordpress.com/2025/03/26/d...
#jazz #ScottRobinson #DanBlock #DannyTobias jazzsky
Bêtabloquants, aspirine : résultats inattendus présentés à l’#ESCcongress 2025
Gilles Montalescot et Michel Zeitouni commentent les essais cliniques REBOOT, ANDAMAN, BETAMI-DANBLOCK, AQUATIC et DAPT-SHOCK.
ms.spr.ly/63320sdUXY
Gilles Montalescot et Michel Zeitouni commentent les essais cliniques REBOOT, ANDAMAN, BETAMI-DANBLOCK, AQUATIC et DAPT-SHOCK.
ms.spr.ly/63320sdUXY
Bêtabloquants, aspirine : résultats inattendus présentés à l’ESC 2025
Gilles Montalescot et Michel Zeitouni commentent les essais cliniques clés menés sur les bêtabloquants et anticoagulants à l’ESC 2025 : REBOOT, ANDAMAN, BETAMI-DANBLOCK, AQUATIC et DAPT-SHOCK.
ms.spr.ly
September 2, 2025 at 3:38 PM
Bêtabloquants, aspirine : résultats inattendus présentés à l’#ESCcongress 2025
Gilles Montalescot et Michel Zeitouni commentent les essais cliniques REBOOT, ANDAMAN, BETAMI-DANBLOCK, AQUATIC et DAPT-SHOCK.
ms.spr.ly/63320sdUXY
Gilles Montalescot et Michel Zeitouni commentent les essais cliniques REBOOT, ANDAMAN, BETAMI-DANBLOCK, AQUATIC et DAPT-SHOCK.
ms.spr.ly/63320sdUXY
I keep seeing danblock fanart on my tumblr and I fear its getting to me
February 6, 2026 at 5:40 PM
I keep seeing danblock fanart on my tumblr and I fear its getting to me
Beta-Blockers after Myocardial Infarction (BETAMI–DANBLOCK trial) nej.md/4oT6aSg
Sacituzumab Govitecan in Triple-Negative Breast Cancer (ASCENT-03 phase 3 trial) nej.md/4ncuUCV
Subscribe to NEJM for the latest medical research: nej.md/subscribe
Sacituzumab Govitecan in Triple-Negative Breast Cancer (ASCENT-03 phase 3 trial) nej.md/4ncuUCV
Subscribe to NEJM for the latest medical research: nej.md/subscribe
November 13, 2025 at 2:02 PM
Beta-Blockers after Myocardial Infarction (BETAMI–DANBLOCK trial) nej.md/4oT6aSg
Sacituzumab Govitecan in Triple-Negative Breast Cancer (ASCENT-03 phase 3 trial) nej.md/4ncuUCV
Subscribe to NEJM for the latest medical research: nej.md/subscribe
Sacituzumab Govitecan in Triple-Negative Breast Cancer (ASCENT-03 phase 3 trial) nej.md/4ncuUCV
Subscribe to NEJM for the latest medical research: nej.md/subscribe
Beta-Blockers after Myocardial Infarction in Patients without Heart Failure (BETAMI–DANBLOCK trial) nej.md/4oT6aSg
High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults (DANFLU-2 trial) nej.md/4lPGMtT
High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults (DANFLU-2 trial) nej.md/4lPGMtT
August 30, 2025 at 7:01 PM
Beta-Blockers after Myocardial Infarction in Patients without Heart Failure (BETAMI–DANBLOCK trial) nej.md/4oT6aSg
High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults (DANFLU-2 trial) nej.md/4lPGMtT
High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults (DANFLU-2 trial) nej.md/4lPGMtT
Debate Over Beta-Blockers in Post-Heart Attack Care Fueled by Conflicting Trials
Conflicting Evidence on Beta-Blockers After Heart Attacks: New Trials Spark Debate Recent medical trials presented at the European Society of Cardiology congress have reignited discussions regarding the use of…
Conflicting Evidence on Beta-Blockers After Heart Attacks: New Trials Spark Debate Recent medical trials presented at the European Society of Cardiology congress have reignited discussions regarding the use of…
Debate Over Beta-Blockers in Post-Heart Attack Care Fueled by Conflicting Trials
Conflicting Evidence on Beta-Blockers After Heart Attacks: New Trials Spark Debate Recent medical trials presented at the European Society of Cardiology congress have reignited discussions regarding the use of beta-blockers in patients recovering from myocardial infarctions (MI), commonly known as heart attacks. Two significant studies, the REBOOT trial and the BETAMI-DANBLOCK trial, have produced contrasting results that may reshape treatment protocols for post-MI patients.
abzac.news
September 2, 2025 at 6:45 AM
Debate Over Beta-Blockers in Post-Heart Attack Care Fueled by Conflicting Trials
Conflicting Evidence on Beta-Blockers After Heart Attacks: New Trials Spark Debate Recent medical trials presented at the European Society of Cardiology congress have reignited discussions regarding the use of…
Conflicting Evidence on Beta-Blockers After Heart Attacks: New Trials Spark Debate Recent medical trials presented at the European Society of Cardiology congress have reignited discussions regarding the use of…
The latest Beyond the Data has @mmamas1973.bsky.social, Dan Atar, and Borja Ibáñez discussing data from the REBOOT-CNIC and BETAMI-DANBLOCK trials at #ESCCongress2025. Watch the full video now: www.tctmd.com/videos/beyon...
September 11, 2025 at 6:23 PM
The latest Beyond the Data has @mmamas1973.bsky.social, Dan Atar, and Borja Ibáñez discussing data from the REBOOT-CNIC and BETAMI-DANBLOCK trials at #ESCCongress2025. Watch the full video now: www.tctmd.com/videos/beyon...
At the recent #ESCCongress2025, @mmamas1973.bsky.social, Dan Atar, and Borja Ibáñez discuss data from the REBOOT-CNIC and BETAMI-DANBLOCK trials, which looked at beta-blockers in post-MI patients without heart failure or impaired LVEF. www.tctmd.com/videos/beyon...
September 9, 2025 at 7:55 PM
At the recent #ESCCongress2025, @mmamas1973.bsky.social, Dan Atar, and Borja Ibáñez discuss data from the REBOOT-CNIC and BETAMI-DANBLOCK trials, which looked at beta-blockers in post-MI patients without heart failure or impaired LVEF. www.tctmd.com/videos/beyon...
【備忘】EHJ Mar.25
MI後にβ遮断薬とプラセボを比較したRCT “BETAMI-DANBLOCK”から、「β遮断薬でプラセボに比べ、臨床上問題となる『抑うつ』や『不安』は増えない」とする事前設定追加解析。
試験参加5,622例中、4.733例を1年間評価。
全文🔗 x.gd/lf1e3
MI後にβ遮断薬とプラセボを比較したRCT “BETAMI-DANBLOCK”から、「β遮断薬でプラセボに比べ、臨床上問題となる『抑うつ』や『不安』は増えない」とする事前設定追加解析。
試験参加5,622例中、4.733例を1年間評価。
全文🔗 x.gd/lf1e3
Beta-blockers, depression, and anxiety after myocardial infarction: the BETAMI-DANBLOCK trial
Symptoms of depression and anxiety are common among patients with myocardial infarction (MI) and associated with reduced health-related quality of life and
x.gd
March 25, 2026 at 11:16 PM
【備忘】EHJ Mar.25
MI後にβ遮断薬とプラセボを比較したRCT “BETAMI-DANBLOCK”から、「β遮断薬でプラセボに比べ、臨床上問題となる『抑うつ』や『不安』は増えない」とする事前設定追加解析。
試験参加5,622例中、4.733例を1年間評価。
全文🔗 x.gd/lf1e3
MI後にβ遮断薬とプラセボを比較したRCT “BETAMI-DANBLOCK”から、「β遮断薬でプラセボに比べ、臨床上問題となる『抑うつ』や『不安』は増えない」とする事前設定追加解析。
試験参加5,622例中、4.733例を1年間評価。
全文🔗 x.gd/lf1e3
「日本医事新報」誌に欧州心臓病学会（ESC）報告が掲載されました。
MI後β遮断薬の有用性を検討しまったく逆の結果となったBETAMI-DANBLOCK／REBOOT-CNICの両試験、AFアブレーション後OAC中止の可否を探ったALONE-AF試験、そしてPCI後DAPT期間の個別化を目指したPARTHENOPE試験——を、現場での議論も含めご紹介しています。
ご笑覧いただけますと幸いです。
記事🔗
x.gd/Gq9QD
MI後β遮断薬の有用性を検討しまったく逆の結果となったBETAMI-DANBLOCK／REBOOT-CNICの両試験、AFアブレーション後OAC中止の可否を探ったALONE-AF試験、そしてPCI後DAPT期間の個別化を目指したPARTHENOPE試験——を、現場での議論も含めご紹介しています。
ご笑覧いただけますと幸いです。
記事🔗
x.gd/Gq9QD
学会レポート─2025年欧州心臓病学会（ESC）［J-CLEAR通信（182）］
– 日本医事新報社
8月29日からマドリード（スペイン）にて、欧州心臓病学会（ESC）学術集会が開催された。参加者は、医療従事者だけで169カ国からの3万3000人以上に及んだという。報告された研究は論文同時公開だけでも200近くを数えたが、ここでは慢性期治療に関する興味深いRCTを紹介したい（9月上旬Web報告を整理）。 TOPIC 1MI後「EF＞40％」例へのβ遮断薬でCV転帰は改善するのか？ 2つのRCTで異...
x.gd
October 23, 2025 at 9:03 AM
「日本医事新報」誌に欧州心臓病学会（ESC）報告が掲載されました。
MI後β遮断薬の有用性を検討しまったく逆の結果となったBETAMI-DANBLOCK／REBOOT-CNICの両試験、AFアブレーション後OAC中止の可否を探ったALONE-AF試験、そしてPCI後DAPT期間の個別化を目指したPARTHENOPE試験——を、現場での議論も含めご紹介しています。
ご笑覧いただけますと幸いです。
記事🔗
x.gd/Gq9QD
MI後β遮断薬の有用性を検討しまったく逆の結果となったBETAMI-DANBLOCK／REBOOT-CNICの両試験、AFアブレーション後OAC中止の可否を探ったALONE-AF試験、そしてPCI後DAPT期間の個別化を目指したPARTHENOPE試験——を、現場での議論も含めご紹介しています。
ご笑覧いただけますと幸いです。
記事🔗
x.gd/Gq9QD